Browsing by Author "Aldemir, M.N."

Now showing 1 - 5 of 5

Chemoradiotherapy Followed by Surgery Versus Observation in Esophageal Squamous Cell Carcinoma
(Zerbinis Publications, 2021) Sakin, A.; Sahin, S.; Aldemir, M.N.; Iliklerden, U.H.; Kotan, M.C.
Purpose: We aimed to examine the effect of esophagectomy after chemoradiotherapy (CRT) or non-surgical follow-up after CRT in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods: A total of 653 patients under follow-up for locally advanced ESCC between 2010-2019 were reviewed for enrollment. Patients with no distant metastasis at the time of diagnosis who underwent esophagectomy or were taken under observation following CRT were included in the study. Overall, 127 eligible patients were included, 55 of whom were male (43.3%) and 72 female (56.7%). Results: After CRT, 59 patients (53.5%) had undergone surgery and 68 (46.5%) were taken under observation. Median disease-free survival (mDFS) was not reached in the group that underwent surgery and was 13 months in the observation group (p<0.001). Median overall survival (mOS) was significantly longer in the operated group (p=0.006). There was no statistically significant difference in DFS and OS between patients who underwent surgery and those included in the observation group after achieving clinical and pathological complete response following CRT (p=0.119, p=0.699, respectively). The multivariate analysis identified surgery and increased CRT response as the factors that affect DFS (p=0.042, p<0.001, respectively). Conclusion: In this study, surgery provided no additional benefit on survival in locally advanced ESCC patients with complete response while prolonged survival was observed in those without complete response. © 2021 Zerbinis Publications. All rights reserved.
The Effect of Cachexia on Survival in Metastatic Gastric Cancer Patients Treated With Best Supportive Care
(Yuzuncu Yil Universitesi Tip Fakultesi, 2020) Sakin, A.; Aldemir, M.N.
In this retrospective study, we aimed to investigate the effect of cachexia on survival in metastatic gastric cancer (GC) patients treated with best supportive care (BSC) using real-life data. From 2015 to 2019, metastatic GC patients who were treated with BSC were included in this study. The study enrolled 53 metastatic GC patients, 36 (67.9%) were male and 17 (32.1%) were female. The median age of the patients was 66 years. The patients were assigned into two groups, according to body mass index (BMI): BMI <18kg/m2 or BMI ≥18 kg/m2 . A total of 18 patients (33.9%) were in the BMI <18kg/m2 group and 35 patients (66.1%) were in the BMI ≥18 kg/m2 group. There was a statistically significant difference between the two BMI groups with a median overall survival (mOS) of 1 month in the BMI <18kg/m2 group and 3 months in the BMI ≥18 kg/m2 group (p<0.001). In the multivariate analyses, age (hazard ratio [HR], 0.97), chronic obstructive pulmonary (HR, 6.53), BMI <18kg/m2 (HR, 2.31), liver metastasis (HR, 3.53), and peritoneum metastasis (HR, 2.31) were associated with OS. In this study, we found that presence of cachexia at the time of diagnosis in metastatic GC patients treated with BSC was associated with shorter survival in comparison to non-cachectic patients. © 2020, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.
The Effect of Obesity on Response To Neoadjuvant Therapy in Locally Advanced Gastric Cancer
(Asian Pacific Organization for Cancer Prevention, 2020) Sakin, A.; Sahin, S.; Sakin, A.; Aldemir, M.N.; Bayram, I.; Kotan, C.
Introduction: The effect of obesity on response to neoadjuvant chemotherapy (NACT) remains unknown. We aimed to investigate the effect of obesity on response to NACT and survival in locally-advanced gastric cancer (GC). Methods: From 2010 to 2019, 142 GC patients with clinical stage III disease who underwent curative surgery after NACT were enrolled. Patients were divided into 3 groups according to body mass index (BMI) as follows; BMI < 25 kg/m2, BMI = 25-30 kg/m2, and BMI > 30 kg/m2. The Mandard tumor regression grading system was used for tumor regression grade (TRG). Results: Of the 142 GC patients, 45(31.7%) were female. The median age was 58 years. BMI was < 25 kg/m2 in 60 (42.3%) patients, 25-30 kg/m2 in 44 (31%) patients, and > 30kg/m2 in 38 (26.8%) patients. The numbers of patients with TRGI-II, TRGIII, and TRGIV-V were 35 (24.6%), 44 (31%), and 63 (44.4%), respectively. There was no statistically significant difference among BMI groups in terms of disease-free survival (DFS) and overall survival (OS) (p = 0.919 and p = 0.398, respectively). According to TRG groups; mDFS was 46 months in TRG I-II, 28 months in TRG III, and 18 months in TRG IV-V (p<0.001). In multivariate analysis, presence of perineural invasion and lymphovascular invasion were the factors affecting TRG. Conclusion: In our study, we found that pre-treatment obesity did not affect the TRG in clinical stage III GC patients. However, a better TRG status was associated with improved survival. © 2020 Asian Pacific Organization for Cancer Prevention.
Efficacy of Gemcitabine Plus Nab-Paclitaxel in Second-Line Treatment of Metastatic Pancreatic Cancer
(Nature Research, 2025) Sezgin, Y.; Karhan, O.; Aldemir, M.N.; Ürün, M.; Erçek, B.M.; Urakcı, Z.; Ergün, Y.
Despite numerous studies on second-line therapies in metastatic pancreatic cancer, there is no randomized study evaluating the efficacy of gemcitabine plus nab-paclitaxel as a second-line treatment. This study aims to examine the efficacy of gemcitabine plus nab-paclitaxel in second-line therapy. In this retrospective study, a total of 218 patients from 23 centers were included. The primary endpoint was progression-free survival (PFS), secondary endpoints included overall survival (OS), treatment efficacy based on ECOG performance status (PS), and tumor marker (CEA, CA 19 − 9) levels. In the second-line treatment with gemcitabine plus nab-paclitaxel, the median PFS was 5.1 months (95% CI, 5.6 to 7.1), and the median OS was 8.6 months (95% CI, 7.3 to 10.0). Median PFS was 6.6 months in patients with normal CEA levels compared to 4.4 months in patients with high CEA levels (P = 0.01). Median PFS was 6 months in patients with ECOG PS 0–1 compared to 3.8 months in patients with PS 2 (P < 0.01). This study demonstrates the contribution of gemcitabine plus nab-paclitaxel in both OS and PFS in second-line treatment of metastatic pancreatic cancer. It was found to be a good option especially for young patients with good ECOG PS. © The Author(s) 2025.
Multiple Primary Synchronous Gastric, Esophageal, and Rectal Cancer and Isolated Esophageal Metastasis From Rectal Cancer: Case Report
(Turkiye Klinikleri, 2021) Sönmez, G.M.; Aytekin, A.; Erten, R.; Aldemir, M.N.; Sakin, A.; Esen, R.
Synchronous tumors are defined as two or more neoplasms either identified simultaneously or within 6 months after the initial diagnosis in the same patient. Herein, we report a 63-year-old man with synchronous gastric, rectal carcinoma, and in situ esophageal carcinoma who also had isolated esophageal metastasis from rectal carcinoma. The patient man was diagnosed with rectal carcinoma. 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography was performed for staging and demonstrated increased 18F-FDG uptake in the rectum lesion as well as in the gastric cardia and corpus. Esophagogastroduodenoscopy was performed. After performing multiple biopsies, histopathological examination of the esophageal specimen demonstrated metastatic adenocarcinoma, in situ esophageal squamous cell carcinoma, and gastric adenocarcinoma. Isolated esophageal metastasis from rectal cancer is a highly rare entity. Gastric and esophageal cancers can be observed simultaneously with colorectal cancers; therefore, we recommend performing routine esophagogastroduodenoscopy for patients diagnosed with colorectal cancer. © 2021 by Turkish Society of Medical Oncology.